文献速递消化道肿瘤放疗

基于STELLAR研究的事后分析:影响直肠癌侧方淋巴结转移的临床病理因素

Post-hoc analysis of clinicopathological factors affecting lateral lymph node metastasis based on STELLAR study for rectal cancer.
PubMed 文献 · Radiother Oncol · 2024-08-30

基于STELLAR III期随机对照研究的事后分析,纳入591例接受新辅助(放)化疗联合根治性切除的局部晚期直肠癌患者,MRI定义侧方盆腔淋巴结转移为短径>7 mm。99例(16.8%)诊断侧方盆腔淋巴结转移,其3年无病生存、总生存、无转移生存显著低于无转移组,侧方盆腔淋巴结转移是影响无病生存、总生存、无转移生存的独立预后因素。

要点

  • 591例中99例(16.8%)MRI诊断侧方盆腔淋巴结转移,多为单侧(79.8%),髂内淋巴结转移更常见(81.8%)。
  • 侧方盆腔淋巴结转移组3年无病生存51.4% vs 68.2%(P<0.001),总生存71.8% vs 84.2%(P=0.006),无转移生存60.8% vs 80.1%(P<0.001)。
  • 侧方盆腔淋巴结转移是影响无病生存(P=0.005)、总生存(P=0.036)、无转移生存(P=0.001)的独立预后因素。

核心结论

  • MRI观察到的侧方盆腔淋巴结转移在局部晚期直肠癌患者中应考虑,尤其是低位直肠癌、N2疾病和肠系膜淋巴结转移人群。
  • MRI诊断的侧方盆腔淋巴结转移是显著且独立的危险因素,与更差的无病生存、总生存、无转移生存相关。

研究设计与样本

  • STELLAR III期随机对照研究的事后分析,纳入591例局部晚期直肠癌患者,均接受新辅助(放)化疗联合根治性切除。
  • 侧方盆腔淋巴结转移定义为磁共振成像(MRI)上短径>7 mm。

主要发现

  • 591例中99例(16.8%)诊断侧方盆腔淋巴结转移,其中单侧转移占79.8%,髂内淋巴结转移更常见(81.8%)。
  • 有无侧方盆腔淋巴结转移两组在直肠分段(P=0.001)、N疾病(P<0.001)、肠系膜淋巴结转移与否(P=0.030)方面存在显著差异。
  • 中位随访时间34.0个月,侧方盆腔淋巴结转移组3年无病生存51.4% vs 无转移组68.2%(P<0.001),总生存71.8% vs 84.2%(P=0.006),无转移生存60.8% vs 80.1%(P<0.001)。
  • 两组局部区域复发无显著差异(11.4% vs 8.5%,P=0.564)。
  • 多因素分析发现侧方盆腔淋巴结转移是影响无病生存(P=0.005)、总生存(P=0.036)、无转移生存(P=0.001)的独立预后因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In post-hoc analyses of phaseIII randomized controlled study(STELLAR), to analyzethe prognostic impact oflateral pelvic lymph node (LPLN)metastasis in locally advanced rectal cancer (LARC). METHODS: LPLN metastasis was defined as a short diameter > 7 mm on magnetic resonance imaging (MRI).The studyincluded 591 patients with LARC.All patients received neoadjuvant (chemo)radiotherapy combined withradical resection. RESULTS: Among 591 patients, 99 (16.8 %) were diagnosed with LPLN metastasis, mostly with unilateral metastasis (79.8 %), with internal iliac lymph node metastasis being more common (81.8 %).Significant differences were found among with and without LPLN metastasis in rectal segmentation (P=0.001),N disease (P<0.001), mesenteric LN metastasis or not (P=0.030). The median follow-up timewas 34.0 months, three-year disease-free survival (DFS),overall survival (OS), andmetastasis-free survival (MFS)were significantly lower in LPLN metastaticgroup than those in LPLN non-metastaticgroup (51.4 % vs. 68.2 %, P<0.001; 71.8 % vs. 84.2 %, P=0.006; 60.8 % vs. 80.1 %,P<0.001), respectively; while there were no significant differences in locoregional recurrence(11.4 % vs. 8.5 %, P=0.564). Multivariate analysis found that LPLN metastasis was an independent prognostic factor affecting DFS (P=0.005), OS (P=0.036),MFS (P=0.001).No significantly survival benefit was observed for the short-term radiotherapy based total neoadjuvant therapy compared to long-term concurrent chemoradiotherapy. CONCLUSIONS: LPLN metastasis observed byMRI should be considered in LARC patients, especially in populations with lowrectal cancer, N2 disease, and mesenteric LN metastasis. LPLN metastasis diagnosed by MRI is a significant and independent risk factor and is associated with worse DFS, OS, MFS.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Chen LN, Jiang J, Jiang LM, et al. Post-hoc analysis of clinicopathological factors affecting lateral lymph node metastasis based on STELLAR study for rectal cancer. Radiother Oncol. 2024. PMID: 39216825. doi:10.1016/j.radonc.2024.110512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。